The tyrosine kinase v-Src modifies cytotoxicities of anticancer drugs targeting cell division

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• The v-Src oncogene drives cell transformation via tyrosine kinase activity.
• v-Src-induced transformation is linked to mitotic abnormalities and chromosome instability.
• v-Src phosphorylates CDK1 at Tyr-15, causing mitotic slippage and affecting drug sensitivity.

Purpose of the Study:

• To investigate if v-Src modifies the cytotoxicity of various anticancer drugs targeting cell division.
• To understand the mechanisms by which v-Src affects drug responses.

Main Methods:

• Cell viability assays with v-Src expressing cells treated with microtubule-targeting agents (MTAs), DNA-damaging drugs, PLK1 inhibitors, and Aurora kinase inhibitors.
• Analysis of mitotic slippage and ploidy generation.
• Assessment of drug-induced cell death.

Main Results:

• v-Src restores viability of cells treated with MTAs and PLK1 inhibitors, but not DNA-damaging drugs.
• v-Src induces mitotic slippage in MTA-treated cells, leading to tetraploid cell formation.
• v-Src expression sensitizes cells to Aurora kinase inhibitors.
• v-Src confers resistance to MTAs via mitotic slippage, potentially increasing malignancy and chromosome instability.

Conclusions:

• v-Src significantly modifies the efficacy of anticancer drugs targeting cell division.
• Src-mediated resistance to MTAs through mitotic slippage poses a risk for enhanced cancer malignancy.
• Targeting cell division pathways in v-Src-expressing cancers requires careful consideration of drug combinations.